You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 19, 2024

CLINICAL TRIALS PROFILE FOR NIVOLUMAB


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for nivolumab

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01024231 ↗ Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma Completed Medarex Phase 1 2009-12-14 The purpose of this study is to determine the safety and tolerability of treatment with BMS-936558 (MDX-1106) in combination with Ipilimumab (BMS-734016) when given at the same time or as a sequenced regimen in subjects with unresectable Stage III or Stage IV malignant melanoma (MEL)
NCT01024231 ↗ Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma Completed Ono Pharma USA Inc Phase 1 2009-12-14 The purpose of this study is to determine the safety and tolerability of treatment with BMS-936558 (MDX-1106) in combination with Ipilimumab (BMS-734016) when given at the same time or as a sequenced regimen in subjects with unresectable Stage III or Stage IV malignant melanoma (MEL)
NCT01024231 ↗ Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma Completed Bristol-Myers Squibb Phase 1 2009-12-14 The purpose of this study is to determine the safety and tolerability of treatment with BMS-936558 (MDX-1106) in combination with Ipilimumab (BMS-734016) when given at the same time or as a sequenced regimen in subjects with unresectable Stage III or Stage IV malignant melanoma (MEL)
NCT01176474 ↗ Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma Active, not recruiting Bristol-Myers Squibb Phase 1 2010-08-13 The purpose of this study is to test the side effects of an investigational vaccine with an immune booster, or 2 different boosters together. Investigators also want to find out its effects on the immune system and whether it will decrease the chance that melanoma will return.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for nivolumab

Condition Name

Condition Name for nivolumab
Intervention Trials
Melanoma 91
Non-Small Cell Lung Cancer 58
Renal Cell Carcinoma 49
Metastatic Melanoma 42
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for nivolumab
Intervention Trials
Carcinoma 278
Melanoma 187
Carcinoma, Non-Small-Cell Lung 181
Lung Neoplasms 167
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for nivolumab

Trials by Country

Trials by Country for nivolumab
Location Trials
Japan 588
United States 4,857
China 373
Australia 367
Canada 333
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for nivolumab
Location Trials
California 296
Texas 284
New York 268
Pennsylvania 243
Florida 200
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for nivolumab

Clinical Trial Phase

Clinical Trial Phase for nivolumab
Clinical Trial Phase Trials
Phase 4 9
Phase 3 95
Phase 2/Phase 3 17
[disabled in preview] 652
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for nivolumab
Clinical Trial Phase Trials
Recruiting 559
Active, not recruiting 286
Not yet recruiting 213
[disabled in preview] 115
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for nivolumab

Sponsor Name

Sponsor Name for nivolumab
Sponsor Trials
Bristol-Myers Squibb 544
National Cancer Institute (NCI) 146
M.D. Anderson Cancer Center 48
[disabled in preview] 42
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for nivolumab
Sponsor Trials
Other 1309
Industry 1064
NIH 149
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.